Methylamine

Methylamine

SCHEMBL2429643

CCCOc1ccc(C(=O)OC)cc1.CN

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.77
RAB9A P51151 3/20 0.68
PLK1 P53350 1/20 0.63
L3MBTL1 Q9Y468 3/20 0.58
TDP1 Q9NUW8 1/20 0.57
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.55
NPC1 O15118 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
MAPK1 P28482 2/20 0.54
KDM4E B2RXH2 2/20 0.54
THRB P10828 2/20 0.54
ALDH1A1 P00352 1/20 0.54
GLA P06280 1/20 0.54
GAA P10253 1/20 0.54
HPGD P15428 1/20 0.54
TSHR P16473 1/20 0.54
CASP1 P29466 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2341097 0.96 MAPT (0.82) MAPTRAB9APLK1L3MBTL1TDP1
SCHEMBL14231641 0.92 MAPT (0.74) MAPTRAB9APLK1L3MBTL1TDP1
SCHEMBL14926537 0.90 MAPT (0.72) MAPTRAB9APLK1L3MBTL1TDP1
SCHEMBL7937774 0.89 MAPT (0.82) MAPTRAB9AL3MBTL1TDP1CA1
Hydroxyamine SCHEMBL8633075 0.88 MAPT (0.74) MAPTRAB9AL3MBTL1TDP1CA1
SCHEMBL1951546 0.87 MAPT (1.00) MAPTRAB9AL3MBTL1TDP1CA1
Benzene SCHEMBL27950703 0.86 MAPT (0.78) MAPTRAB9AL3MBTL1TDP1SMN1; SMN2
SCHEMBL1988905 0.86 MAPT (0.77) MAPTRAB9ASMN1; SMN2NPC1TSHR
SCHEMBL28818862 0.86 MAPT (0.66) MAPTRAB9APLK1L3MBTL1TDP1
SCHEMBL12125149 0.86 MAPT (0.66) MAPTRAB9APLK1L3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
CN-100471838-C VLA-4 inhibitors DAIICHI SEIYAKU CO (JP) 2009-03-25 CN disclosed
CN-100396680-C Vla-4 inhibitors DAICHI PHARMACEUTICAL CO LTD (JP) 2008-06-25 CN disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
CN-1699363-A Vla-4 inhibitors DAICHI PHARMACEUTICAL CO LTD (JP) 2005-11-23 CN disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
CN-1483024-A Vla-4 inhibitors ��һ��������ҩ��ʽ���� 2004-03-17 CN disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 MAPT 4631/4885RAB9A 2530/4885PLK1 4546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.